In the future, stem-cell-based therapies could offer new approaches to treat kidney disease and reduce the incidence of ESRD (end-stage renal disease), but, as yet, research in this area is only being conducted in rodents and it is not clear whether or when it could be applied to human patients. Drug therapies, on the other hand, have been very effective at delaying the progression of kidney disease, but, for various reasons, current drug regimes are not suitable for all patients. A greater understanding of the molecular mechanisms that underlie disease progression in chronic kidney disease could help to identify novel drug targets. However, progress in this area is currently hindered due to the lack of appropriate in vitro culture systems for important renal cell types, such as proximal tubule cells and podocytes. This problem could be overcome if it were possible to direct the differentiation of kidney stem cells to renal cell types in vitro. In the present review, we highlight the potential of surface gradients of small chemical functional groups to direct the differentiation of kidney stem cells.
Introduction
It is now recognized that renal disease is a global public health problem, with the incidence and prevalence of ESRD (endstage renal disease) rising annually. Evidence suggests that one of the main reasons for the rapid increase in ESRD is the increased incidence of diabetes, which is the most common cause of ESRD. At present it is expected that one out of ten individuals will suffer from renal-associated diseases at some stage during their life. Current treatment options for ESRD are dialysis and renal transplantation, which, apart from their significant drawbacks in terms of increased morbidity, mortality and poor quality of life, are also placing an increasing burden on the economies of both developed and developing countries. For instance, in the U.S.A., the current cost of treating ESRD is >US$50 000 per patient per year, and this rises to >US$100 000 per year for patients with co-morbidities [1] . In Europe, there has recently been a dramatic increase in the ESRD population, particularly in the 65+ age group, where the incidence of ESRD doubled from ∼210 per million in 1992 to ∼430 per million in 2005 [2] . A major challenge of the 21st Century will be to devise medical interventions that prevent the onset of ESRD, which usually develops from a progressive worsening of chronic renal disease. In most cases, however, there is a time window of several years from the onset of mild/moderate kidney disease to the development of ESRD, which could present an opportunity to design therapies aimed at preventing disease progression.
The potential of stem cell therapies to prevent ESRD
In mammals, nephron formation is completed by birth or in the early postnatal period, and mature kidneys are unable to generate new nephrons in response to damage. If a critical number of nephrons are lost, the kidney compensates by increasing the glomerular filtration rate, which can lead to glomerular hypertrophy, hyperfiltration and glomerular hypertension. The high pressure generated within the glomerulus damages the podocytes and causes increased levels of protein to enter the tubular lumen, causing tubule-interstitial inflammation and fibrosis [3] . Consequently, the hypertrophied nephrons tend to become sclerotic and a vicious circle ensues as nephron loss increases the demand on the remaining nephrons, with the ultimate end point being ESRD (Figure 1 ). Stem-cell-based therapies aimed at preventing ESRD will thus need to focus on repairing or replacing damaged nephrons in patients with renal disease. It has been shown that fetal kidney progenitor cells can generate new nephrons in a rodent model of chronic kidney disease [4] . Importantly, animals that received the fetal cell implants showed improvement in renal function and survived for longer than sham-operated controls [4] . This experiment suggests a potential therapy for the treatment of chronic kidney disease, whereby kidney progenitors derived either directly from aborted human fetuses, or indirectly from appropriate stem cell types, could be expanded in culture, seeded on to biomaterial scaffolds and implanted into the diseased kidneys. To develop this strategy, a necessary first step would be to establish which progenitor/stem cell types show true nephrogenic potential and are able to generate all cell types found in the nephron. As part of the European Network, 'KIDSTEM' [5] , an ex vivo model system has recently been established to investigate the nephrogenic potential of various stem cell types [6] . In this model, labelled stem cells are incorporated into disaggregated mouse kidney rudiments and, following a period of ex vivo culture, are analysed to establish which cell types and structures the stem cells can generate. Results to date indicate that some stem cell types, such as mouse ESC (embryonic stem cell)-derived mesoderm [7] and mouse KSCs (kidney stem cells) [8] , show good nephrogenic potential. Until recently, a consensus view has been that ESCs would be unsuitable for stem cell therapies in humans due to ethical and safety issues; however, in pre-clinical studies, it has recently been shown that ESCs can be safely and effectively used to treat age-related macular degeneration [9] , and clinical trials using human ESCs to treat patients with this condition have now been approved and will soon take place in the U.K. [10] . Although the aforementioned studies show that stem cells could have potential for future renal regenerative therapies, as yet the feasibility of such approaches remains to be established. For instance, to be effective, the stem-cellderived renal tissue would need to be adequately supplied by the renal vasculature of the host, be correctly oriented, and become connected to the collecting tubules and ureters.
The potential of drug therapies to prevent ESRD
It is known that the RAAS (renin-angiotensin-aldosterone system) plays a key role in promoting ESRD progression in both diabetic and non-diabetic nephropathies by increasing glomerular hypertension and hyperfiltration [11] . The main effector of RAAS is AngII (angiotensin II), which raises intraglomerular pressure by constricting the efferent arterioles and causes hyperfiltration by mediating contraction of the podocyte foot processes [12] . AngII also stimulates the secretion of aldosterone, the final component of the RAAS, which promotes ESRD progression through various mechanisms, such as promoting fibrosis and inflammation [13, 14] . For this reason, the mainstay of treatment for diabetic and some non-diabetic nephropathies is RAAS inhibition with ACEIs (angiotensin-converting-enzyme inhibitors) and/or ARBs (AngII receptor blockers). Although these drug therapies are limited in their ability to reverse chronic renal disease, especially in cases where scarring has already occurred, they are very effective at preventing further damage, and can thus significantly delay the onset of ESRD [15] [16] [17] . However, not all patients respond to ACEI/ARB therapy, and some continue to secrete high levels of aldosterone [18] , whereas others are unable to continue treatment due to hyperkalaemia and other side effects. It would therefore be beneficial to understand the mechanisms that underlie RAASinduced disease progression in order to identify novel drug targets downstream of aldosterone. For instance, it is known that one effect of aldosterone is to induce synthesis of TGF-β (transforming growth factor-β) [19] , a growth factor which promotes fibrosis through induction of ECM (extracellular matrix) genes and inhibition of ECM turnover [14] . However, despite the well-established role of TGF-β in renal fibrosis, it is not year clear which renal cell types synthesize this growth factor in response to aldosterone.
At present, elucidation of the molecular mechanisms underlying renal disease progression and the development of novel drug therapies is inhibited because of the lack of appropriate renal cell culture systems. Of particular value would be culture systems for the propagation of PTCs (proximal tubule cells) and podocytes, for both of these cell types are thought to play a crucial role in the development of diabetic nephropathy [20, 21] . A problem with established PTC lines is that they do not display the typical biochemical and transport properties of PTCs in vivo [22] , and podocyte lines can only be established through viral immortalization [23] . Primary PTC and podocyte cultures are thus generally preferred for in vitro studies, but are problematic because of limited scaleup potential. Furthermore, human renal tissue is scarce, and samples available for cell culture are usually restricted to the normal regions of kidneys affected with renal carcinoma. Progress in this field would be greatly enhanced if it were possible to generate renal cell types in culture from a population of self-renewing stem cells, for this would circumvent many of the problems associated with limited tissue availability and would provide scale-up opportunities for drug screening.
Stem-cell-derived PTCs and podocytes
Several studies have investigated the potential of ESCs and their mesodermal derivatives to generate renal cell types [7, 24, 25] . Differentiation assays have included culturing the ESCs in suspension culture as embryoid bodies in the presence of exogenous growth factors [24] , integrating the ESCs into mouse kidney rudiments ex vivo [7] and transplanting the ESCs into neonatal mouse kidneys in vivo [25] . Although many of these studies indicate that ESCs do have the potential to generate renal cell types, as yet, it has not been possible to direct their differentiation to the renal lineage in a two-dimensional culture system.
In recent years, several groups have demonstrated the presence of kidney progenitor cell and KSC populations in rodent and human kidney [26] [27] [28] [29] [30] [31] . A characteristic of most of these KSC populations is that they are able to differentiate in vitro to generate various renal cell types, although the in vitro functionality of these cells has not yet been tested [26, 27, [29] [30] [31] . Furthermore, although a number of reports have indicated that KSCs can give rise to podocytes in vitro, this is usually based on the expression of one or two podocyte markers [30, 31] and, morphologically, these cells bear little resemblance to primary podocytes; the typical characteristics of which include a large cytoplasmic to nuclear ratio, arborization and a tendency to be binucleate [32] . The inability of KSCs to generate true podocytes in vitro is likely to be due to deficiencies in the culture system, for it has recently been demonstrated that a KSC line isolated from human cortex can generate podocytes in a mouse model of induced nephropathy [31] . To date, most protocols aimed at directing the differentiation of KSCs have involved the use of inductive medium containing retinoic acid [30, 31] , and the role of modified substrates in regulating differentiation has not been tested previously. It has recently been shown that culture substrates comprising small-molecule chemical functional groups can regulate the differentiation of ECSs, mesenchymal stem cells and neuronal stem cells [33] [34] [35] , which raises the possibility that functional groups might also be effective in directing KSC differentiation.
Figure 2 Schematic diagram of gradientizer technology
The gradientizer comprises a reactor for plasma deposition equipped with a motorized stage which moves a sample holder in the x-direction.
The speed and travel distance of the stage is computer-controlled. A mask is placed above the sample holder which allows deposition of a predetermined chemical composition only at a chosen position on the surface of the sample. Gradients of chemistry are achieved by continuously exchanging the precursor for film deposition introduced in the plasma chamber in a controlled manner (e.g. monomer 1 is exchanged with monomer 2) and simultaneously moving the samples under the mask in the x-direction via the x-stage. For example, in order to achieve gradients of -NH 2 groups, first a vapour of octadiene (pure hydrocarbon) is introduced into the plasma chamber which is subsequently exchanged by allylamine (a monomer carrying functional amine groups). The possibility to control all parameters (movement of the x-stage and flow rate of both monomers) allows gradients of surface functional chemical groups to be produced in a controlled manner.
The potential of chemically modified substrates to direct the differentiation of KSCs
It has previously been shown that substrates modified with -NH 2 functional groups can promote the differentiation of neural stem cells to neurons [35] . At present, it is not clear how the -NH 2 groups elicit these effects, but a previous study suggests that it is likely to be due to differential binding and/or presentation of ECM molecules, which affects cell adhesion and spreading [36] . We have recently investigated the effect of -NH 2 groups on the differentiation of a clonal kidney stem cell line (KSC:H6) derived from postnatal mouse kidney [8] . In order to test the effect of a range of -NH 2 concentrations on a single substrate, we have made use of a novel gradient technology [34] , where a process of plasma polymerization is used to deposit a concentration gradient of the functional group on a glass coverslip (Figure 2) . Results showed that differentiation of proximal-tubule-like cells appeared to be maximal within the middle region of the gradient, as shown by the expression of the proximal tubule markers alkaline phosphatase and aquaporin 1. In contrast, cells with podocyte-like morphology and high expression levels of the podocyte marker WT1 (Wilms' tumour 1) were more prevalent at the high point of the gradient (H. Shahidipour, P. Murray and K. Vasilev, unpublished work). The advantage of gradient technology is that it enables rapid identification of the functional group concentration that promotes differentiation to the required cell type. Once this has been established, homogeneous substrates can be prepared where the whole surface is coated with the optimal concentration of the functional group.
Summary
Recent studies have shown that stem cells exist in mammalian kidneys, which have the potential to generate PTCs and podocytes in vivo following transplantation into rodent injury models. To date, however, little work has been done to establish culture conditions that are able to direct the differentiation of KSCs in vitro. If directed differentiation could be achieved, KSCs could have useful applications in (i) understanding the mechanisms of kidney disease progression, (ii) drug discovery, and (iii) toxicology studies. 
